© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
September 20, 2019
Q&A With Moshe Yair Levy, MD: Weighing Risks and Benefits With the Use of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
Chronic myeloid leukemia is a rare type of cancer, and tyrosine kinase inhibitors have become the standard guideline-recommended treatment for patients with BCR-ABL1–positive or Ph-positive CML.